Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling

Item

http://www.wikidata.org/entity/Q36402698

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Trifunctional antibody ertumax ...... ivity and downstream signaling

@ast

Trifunctional antibody ertumax ...... ivity and downstream signaling

@en

type

Item

label

Trifunctional antibody ertumax ...... ivity and downstream signaling

@ast

Trifunctional antibody ertumax ...... ivity and downstream signaling

@en

prefLabel

Trifunctional antibody ertumax ...... ivity and downstream signaling

@ast

Trifunctional antibody ertumax ...... ivity and downstream signaling

@en

P1476

Trifunctional antibody ertumax ...... ivity and downstream signaling

@en

P2093

Gero Brockhoff

http://www.w3.org/2001/XMLSchema#string

Olaf Ortmann

http://www.w3.org/2001/XMLSchema#string

Simone Diermeier-Daucher

http://www.w3.org/2001/XMLSchema#string

Stefan Buchholz

http://www.w3.org/2001/XMLSchema#string

P2860

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Untangling the ErbB signalling network

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation

Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation

Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1

Computer program for determining fluorescence resonance energy transfer efficiency from flow cytometric data on a cell-by-cell basis.

Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation.

P304

614-622

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/MABS.21003

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simone Diermeier-Daucher

Gero Brockhoff

P577

2012-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22820509

http://www.w3.org/2001/XMLSchema#string

P921

immunology

P932

3499302

http://www.w3.org/2001/XMLSchema#string